AstraZeneca Collaborates with CSPC to Develop Innovative Lp(a) Inhibitor

AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.Under this agreement, AstraZeneca will gain access to CSPC's preclinical candidate YS2302018, an oral Lp(a) inhibitor. This drug is aimed at developing a new lipid-lowering therapy and can be used as a standalone or combination treatment for various cardiovascular diseases, including in combination with the oral small m ...